Dr. Terry Day received his medical degree from the University of Oklahoma. He completed his residency at Louisiana State University before pursuing a fellowship in head and neck oncologic surgery at the University of California, Davis and in craniomaxillofacial surgery at Inselspital-Bern in Bern, Switzerland. Following fellowship, he joined the faculty in the Department of Otolaryngology -- Head and Neck Surgery at Vanderbilt University Medical Center in Nashville, Tennessee and is now professor, vice chair and director of the Division of Head and Neck Oncologic Surgery in the Department of Otolaryngology -- Head and Neck Surgery at the Medical University of South Carolina in Charleston. He also serves as director of the head and neck tumor center at the NCI-designated Hollings Cancer Center at MUSC and has a joint appointment in the Department of Craniofacial Biology, Department of Stomatology and College of Graduate Studies.
Dr. Day currently serves as immediate past-president of the American Head and Neck Society and serves on the council of the International Academy of Oral Oncology while having completed a four-year term on the board of directors of the American Academy of Otolaryngology -- Head and Neck Surgery. He has served as a senior examiner with the American Board of Otolaryngology. He has also served on the National Cancer Institute’s head and neck steering committee, head and neck surgical subcommittee for RTOG and head and neck working group for the American College of Surgeons oncology group. Dr. Day volunteers his time as president of the Head and Neck Cancer Alliance, Inc., as treasurer of Charleston Moves, and in 1998 started the inaugural international Oral and Head and Neck Cancer Awareness Week (OHANCAW).
Since completion of his fellowship, Dr. Day has limited his clinical practice to patients with tumors of the head and neck region, including robotic surgery, oropharyngeal, skull base, thyroid, skin cancer and salivary gland tumors. He also is active in research in molecular diagnostics and therapeutics in head and neck cancer.